ArticleCancer diagnosis & prognosis
The Role of HMGA1 and Height in Breast Cancer Risk and Prognosis: Insights from UK Biobank Data.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Tall women are more likely to develop breast cancer (BC). High Mobility Group AT-Hook 1 (HMGA1), an oncofetal protein, plays a role in BC progression. Variants near HMGA1 have been associated with increased height. This study examines the relationship between HMGA1, height, and BC risk and prognosis using UK Biobank data. Patients and Methods: Data from 10,527 women with invasive BC were analyzed. Subjects were grouped by height: short (<155 cm), medium (155-175 cm), and tall (>175 cm). HMGA1 SNP rs41269028, a single nucleotide intron variant, was evaluated for its influence on height, BC risk, and survival. Statistical analysis included Fisher's exact test, regression models, and survival analysis using the log-rank test. Results: HMGA1 SNP rs41269028 carriers (CT+TT) were taller (162.88 cm) compared to homozygotes for the major allele (162.29 cm, Conclusion: While HMGA1 influences height, no direct association with increased BC risk or poor prognosis in tall women was demonstrated. Nevertheless, tall women with BC had worse survival, suggesting height might be considered in treatment decisions. Future studies should explore mechanisms linking height to BC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.